Abstract
Since its emergence in December 2019 in Wuhan, China, more than three years, and a half has passed, yet the world is still grappling with the far-reaching impacts of the COVID-19 pandemic. Many countries endured a devastating blow during the second wave of COVID-19, witnessing a significant rise in severe cases among children and instances of multisystem inflammatory syndrome in children, surpassing the numbers seen during the initial wave of the pandemic [1]. While numerous countries have successfully developed effective COVID-19 vaccines for adults, options for pediatric populations have only recently emerged. The Drugs Controller General of India (DCGI) granted emergency approval for the use of COVISHIELD and COVAXIN in pediatric patients aged 12 years and older [2]. However, despite considerable research efforts, a definitive cure or treatment for COVID-19 remains elusive. Several drugs, including remdesivir, casirivimab/imdesivimab, ivermectin, baricitinib, and tofacitinib, have garnered significant attention, but none can be hailed as a panacea [3].
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
